← Back to patent-cliff list
Lavengratinib
Tier C — Watch / tradeLavengratinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR2, FGFR3
Indications (approved)：软骨发育不全, Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Oesophageal cancer
Regional status
US
Phase I
2022-06-30
EU
-
China
Phase II
2024-11-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lavengratinib?
Approved indications include: 软骨发育不全, Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Oesophageal cancer.
When does the Lavengratinib patent expire?
No public expiry year is available for Lavengratinib yet; this page updates once verified.
How do I get a quote for Lavengratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01